The largest database of trusted experimental protocols

15 protocols using turbofectin 8.0 transfection reagent

1

Stable Transfection of HOXB13 in PNT2 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
PNT2 cells were transfected with the four HOXB13 expression vectors (Wt and mutated) and with the control vector (Entry) using TurboFectin 8.0™ transfection reagent (Origene). Briefly, one day before transfection, PNT2 cells were plated in 60mm dishes at a density of 1.5×105 in complete growth medium, in order to reach a confluence of approximately 60% at the day of transfection. For each transformation, 250μL of Opti-MEM medium (GIBCO®) were mixed with TurboFectin 8.0™ and incubated at room temperature for five minutes. The vector DNA was added and incubated at room temperature for 30 minutes. In order to achieve the best transfection efficiency, three different ratios of TurboFectin:DNA were used for each vector: 3:1 (7.5μL of TurboFectin for 2.5μg of DNA), 3:2 (7.5μL of TurboFectin for 5μg of DNA) and 6:1 (15μL of TurboFectin for 2.5μg of DNA). The TurboFectin:DNA containing mixtures were then added dropwise to the cells and incubated for 48 hours at regular growth conditions. At this point, cells were exposed to selective pressure by adding regular growth medium supplemented with 450µg/µL of G418 (GIBCO®). Four to five weeks later stable cell populations were obtained.
+ Open protocol
+ Expand
2

Caveolin-1 Modulation in Alveolar Epithelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary cultured AEC-II were seeded onto Transwell Clear inserts and cultured to 60–70 % confluence before transfection. For Cav-1-siRNA transfection, cells were transfected with 10 nm of a rat Cav-1-specific siRNA (5’-GGCAUAGCACAAGUAAUAGUCUGTA-3’; Cat.# SR500200; OriGene Technologies, Rockville, MD, USA) or 10 nm of a non-silencing scrambled control siRNA (Cat.#SR30004;OriGene Technologies) using a siTran 1.0 transfection reagent (OriGene Technologies), according to the manufacturer’s protocol. For Cav-1-cDNA transfection, cells were exposed to hyperoxia (85 % O2 and 5 % CO2) and transfected with Cav-1 cDNA plasmid (1 μg/mL; Cat.#RR200414; OriGene Technologies) or with an empty vector plasmid (1 μg/mL; Cat.#PS100001; OriGene Technologies) as control using Turbofectin 8.0 transfection reagent (OriGene Technologies), following the manufacturer’s instructions.
Cav-1 mRNA and protein expression levels were monitored using reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis, respectively, to determine the best concentration of Cav-1-siRNA or Cav-1 cDNA plasmid for transfection and the best post-transfection time for the lowest and highest Cav-1 expression. Cells transfected with siRNA or cDNA plasmid were harvested at 48 and 72 h after transfection, respectively, before further experiments.
+ Open protocol
+ Expand
3

Stable Knockdown of PGC1α in Pancreatic Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The Colo357 pancreatic cancer cells with stable PGC1α knockdown (KD) and scrambled (SCR) control cells were generated using a PGC1α human shRNA plasmid kit (Origene, TG310260). LGKC1 cells with stable KD of PGC1α were generated using a mouse PGC1α shRNA plasmid (Santa Cruz, Cat# Sc-38885-SH) and control shRNA plasmid B (Sc-108065). Cells were transfected with SCR and shRNA plasmids using TurboFectin 8.0 transfection reagent (Origene, TF81001). 72 hr after transfection, GFP+-transfected Colo357 cells were sorted using FACS. Stably transfected cells were selected by treating with puromycin (2 μg/mL). The efficiency of PGC1α KD was examined using western blot and RT-PCR assays.
+ Open protocol
+ Expand
4

Confirming H7HA Gene Expression by Indirect Immunofluorescence

Check if the same lab product or an alternative is used in the 5 most similar protocols
An indirect immunofluorescent assay was utilized to confirm H7HA gene expression as described previously [35 (link)]. Briefly, human rhabdomyosarcoma (RD) cells were plated on two-well chamber slides (BD Biosciences), at a density to obtain 60-70% confluency the next day in complete DMEM medium with 10% FBS (GIBCO) and allowed to adhere overnight. The cells were transfected with pH7HA and the control plasmid pGX0001 (1 ug/well) using TurboFectin8.0 Transfection Reagent (OriGene) according to the manufacturer’s instructions. Forty-eight hours later, the cells were washed gently three times with 1XPBS and fixed on slides using ice cold methanol for 10 min. The cells were incubated with anti-H7N9 HA mouse monoclonal antibody (Sino Biological Inc., Cat# 11082-MM04) at a 1:400 dilution for 2h at room temperature. The slides were then incubated with the Alexa 555-conjugated anti-mouse secondary antibody (Cell Signaling Technology) for 60 min in the dark, and analyzed by fluorescent microscopy (Leica DM4000B, Leica Microsystems Inc, USA) using the SPOT Advanced software program (SPOT Diagnostic Instruments, Inc).
+ Open protocol
+ Expand
5

Transfection and Nano-CuO Exposure Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Transfection was performed as described in our previous study with modifications [13 (link)]. Briefly, BEAS-2B cells were seeded in the inserts and incubated for 12 h, then U937* cells were seeded at a ratio of 1:1 or 9:1 (BEAS-2B:U937*) onto the BEAS-2B cell layer in antibiotic-free medium supplemented with 10% FBS and allowed to attach. Cells were then transfected with a mixture of 6 µL of TurboFectin 8.0 Transfection Reagent (Origene, Rockville, MD, USA) and 30 nM of MMP-3 siRNA (Ambion, Carlsbad, CA, USA) in a total volume of 1 mL antibiotic-free and FBS-free medium for 6 h. Afterward, 1 mL medium containing 2 times FBS and antibiotics was added, and the cells were incubated for another 12 h. Silencer™ Select Negative Control No. 2 siRNA (Ambion, Carlsbad, CA, USA) was used as a negative control. After exposure to Nano-CuO for 12 h, the conditioned media were collected and the roles of MMP-3 in the cleavage of OPN and activation of fibroblasts were determined.
+ Open protocol
+ Expand
6

miR-375 Regulation of CCND2 3'UTR

Check if the same lab product or an alternative is used in the 5 most similar protocols
A reporter construct containing a binding site at CCND2 3′UTR for miR-375 (GeneCopoeia, Rockville, MD, USA) was introduced into PC-3 cells using Turbofectin 8.0 transfection reagent (Origene, Rockville, MD, USA). A vector without CCND2 3′UTR (GeneCopoeia) was used as experiment control. Vectors were co-transfected along with pre-miR-375 as described. Luciferase activity was assessed with the Secrete-Pair™ Dual Luminescence Assay Kit (GeneCopoeia, Rockville, MD, USA) according to the manufacturer’s instructions. Experiments were performed in triplicates at 48 and 72 h following co-transfection. At 72 h, miR-375 levels were measured by RT-qPCR to confirm its forced or silenced expression.
+ Open protocol
+ Expand
7

Nano-CuO Induced EMT and MMP-3 Silencing

Check if the same lab product or an alternative is used in the 5 most similar protocols
Transfection was performed following the protocol provided by Thermo Fisher. Briefly, 1.5 × 105 BEAS-2B cells per well were seeded into six-well plates in antibiotic-free RPMI1640 supplemented with 10% FBS. The cells were incubated until 70-80% confluency. Cells were then transfected with a mixture of 6 μL of TurboFectin 8.0 Transfection Reagent (Origene, Rockville, MD) and 40 nM of MMP-3 siRNA (Ambion, Carlsbad, CA) in a total volume of 2 mL antibiotic-free and FBS-free RPMI 1640 medium for 24 h. After transfection, the cells were treated with Nano-CuO for another 48 h. The transfection efficiency was determined by MMP-3 expression by Western blot, and the cells were also harvested for Western blot to examine the role of MMP-3 in Nano-CuO-induced EMT. Silencer™ Select Negative Control No. 2 siRNA (Ambion, Carlsbad, CA) was used as a negative control.
+ Open protocol
+ Expand
8

Generation of Dnaic2 Knockdown Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dnaic2 KD mice were generated as described by Zhang et al.22 Briefly, we first isolated and then cultured female germline stem cells (FGSCs) from ovaries of CD‐1 mice in the short‐term. FGSCs were then cultured for 3‐5 days and were transfected with the pRS‐U6‐shDnaic2‐SV40‐Puro vector using TurboFectin 8.0 transfection reagent according to the manufacturer's instructions (OriGene). After 48 h, the FGSCs were transplanted into ovaries of recipients sterilised by chemotherapy. The recipient mice were mated to wild‐type mice. The genotypes were then identified by PCR and Southern blotting. PCR was performed using 1 μg genomic DNA from mouse tails with primer set (sense: 5′‐TCGACCCTGTGGAATGTGT‐3′; anti‐sense: 5′‐GGGCTTGTACTCGGTCAT‐3′) specific for SV40 early promoter. Southern blotting was used to confirm the results of Dnaic2 KD mice, and was performed according to the method mentioned above.22 Finally, western blotting was carried out using rabbit anti‐DNAI2 or anti‐β‐tubulin (see below).
+ Open protocol
+ Expand
9

CRISPR-Mediated Vaccinia Virus Engineering

Check if the same lab product or an alternative is used in the 5 most similar protocols
A total of 2 × 106 CV-1 cells were seeded in a 6-well plate a day before transfection. Cells at 60–70% confluency were transfected with 1 µg each of plasmid encoding Cas9HFc and gRNA using 6 µL of TurboFectin 8.0 transfection reagent (Origene Technologies, Rockville, MD, USA) in 250 µL of opti-DMEM (Thermo Fisher Scientific, Waltham, MA, USA). At 24 h post-transfection, cells were infected with CAL1 VACV at an MOI of 0.02 in high glucose DMEM supplemented with 2% FBS. Two hours after viral infection, the cells were washed with PBS. 1.5 mL DMEM was added to the wells and the plate was incubated at 37 °C with CO2 for 30 min before being transfected with 2 µg of the donor plasmid generated above. The cells were further incubated at 37 °C with 5% CO2 and in a humidified atmosphere for 24 h. The mixture of infected/transfected cells was harvested and stored at −80 °C until the virus was screened and purified.
+ Open protocol
+ Expand
10

Silencing PRDX3 in Breast Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
MDA-MB-231 cells were transfected with shRNA targeting PRDX3 (shPRDX3) or scrambled shRNA cassette (sh-NT) using Turbofectin 8.0 transfection reagent (Origene Technologies, Inc., Rockville, MD, USA), according to the manufacturer’s instruction. Cells were then selected by puromycin dihydrochloride. siRNA transient transfection was conducted in BT-549 cells using a targeting pool of 4 siRNAs from Dharmacon (Chicago, IL, USA) as described previously [21 (link)].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!